Artiva Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- $248.6M
- Website
- http://www.artivabio.com
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT06265220
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸University of California, San Diego, San Diego, California, United States
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT05678205
- Locations
- 🇺🇸
Oregon Health Science University (OHSU), Portland, Oregon, United States
🇰🇷The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT04673617
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸UF Health Shands Cancer Hospital, Gainesville, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath